Dr. Sergio Baranzini of UC San Francisco recently led an international consortium of researchers in a new study of multiple sclerosis (MS). In a press release on Multiple Sclerosis…
Near the start of August 2022, biotechnology company Inmagene Biopharmaceuticals ("Inmagene") and biopharmaceutical company HUTCHMED shared via news release that the first participant had been dosed in a Phase…
Don't forget to check out Part 1, where we discussed what multiple sclerosis (MS) is, went over Mo's diagnostic journey, and began talking about the importance of awareness. Treating Multiple Sclerosis…
For as long as she can remember, 30-year-old Ankona “Mo” Das has loved traveling. Traveling has provided a way to break out of her shell, to experience new landscapes, and…
Currently, there is no way to determine when a relapse will occur in relapsing and remitting multiple sclerosis (MS), one of the two main forms of MS. However, this may…
What causes “attacks,” or periods of intense symptoms, in those with multiple sclerosis (MS)? In the past, research has suggested that viral infections or even certain bacteria could play a…
In the past, many researchers have hypothesized a link between multiple sclerosis (MS) and different viruses or viral infections. While these hypotheses are varied in nature, there has rarely been…
Past research has shown that rogue Th17 cells could help spur the manifestation of autoimmune conditions like multiple sclerosis (MS). But why do these cells go wrong and how could…
Biogen Inc. recently announced data that included extended results from its earlier Phase 3b NOVA study on the administration of natalizumab and the evaluation of the drugs Tysabri® and Vumerity. …
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
A recent article from Healthline highlighted the similarities and differences between two neurological diseases, myasthenia gravis (MG) and multiple sclerosis (MS). Myasthenia Gravis Deriving from the Greek and Latin words…
In 2019, the United States approved Vumerity (diroximel fumarate) to treat adult patients with relapsing-remitting (R/R) multiple sclerosis (MS). Now, two years later, the European Union has approved this…
Atara Therapeutics has released data from its Phase 1 open-label extension (OLE) trial of ATA188, a treatment for progressive multiple sclerosis (MS). This allogeneic T-cell immunotherapy targets B cells and…
The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was held last week from the 13th to the 15th. This event is the largest…
Kristin woke up the morning of her 19th birthday with a startling realization: she was unable to speak. It was hard to describe the feeling, but when she tried to…
Actress, dancer, and producer Christina Applegate is best known for her roles in Dead to Me, Married...with Children, Samantha Who?, and Up All Night. But now, she has revealed a new role: a member…
A new study published in the journal Scientific Reports has helped explain the differences between neuromyelitis optics spectrum disorder (NMOSD) after optic neuritis (ON) and multiple sclerosis (MS). Although previous studies have…
According to a story from express.co.uk, multiple sclerosis (MS) is a neurological illness that can have major impacts on the lives of its patients. As a condition that can be…
In a review posted on dovepress.com, monoclonal antibodies have established themselves as an important tool in the management of multiple sclerosis in both the relapsing-remitting form and the progressive form.…
Have you ever heard of isoflavone? Well, isoflavone is part of a class of phytoestrogens, or plant-based compounds which resemble estrogen. According to Medical XPress, research from Dr. Ashutosh Mangalam,…
Komodo Health and PicnicHealth have just announced that they have partnered together in effort to combine their data and better serve patients. This data will then be made accessible to…
According to Multiple Sclerosis News Today, the European Commission (EC) recently approved PONVORY (ponesimod) for the treatment of adult patients with relapsing and remitting (R/R) or active secondary progressive (SP)…
According to an article in Biospace, Biogen, a biotechnology company headquartered in Cambridge, Massachusetts, presented new data on its multiple sclerosis (MS) therapies at the virtual Meeting of the American…
Currently, multiple sclerosis (MS), an autoimmune and neurological disorder, is considered either progressive or relapsing-remitting. But could there be additional subtypes? According to new research, yes. As explained in Medical…
Around 30% of all patients with relapsing-remitting multiple sclerosis (RRMS) experience some type of cognitive impairment or decline at the time of diagnosis. Around 50% of patients experience some of…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
